

## Special Issue

# Vaccines Based on Dendritic Cells: Breaking Barriers to New Immune Response Approach

### Message from the Guest Editor

Dendritic cells (DCs) are versatile cells that bridge the gap between innate and adaptive immune responses. They are potent antigen-presenting cells that control both T cell immunity and tolerance. DCs are often downregulated in diseases such as cancer, where they are called tolerogenic DCs and have a crucial role in inducing peripheral tolerance. Recent studies on vaccines based on nucleic acids such as DNA or mRNA have shown remarkable results in treating diseases such as COVID-19 and multiple solid tumors. We invite contributions of original reports, observations, or reviews to highlight (i) their role in preventing relapses in cancer, (ii) the metabolic signaling pathway target, (iii) the ability to cross the blood–brain barrier in pathological processes or as a vaccination strategy, and (iv) recent advances in novel therapeutic vaccines based on dendritic cells.

### Guest Editor

Prof. Dr. Soledad Lopez-Enriquez

Department of Medical Biochemistry, Molecular Biology, Immunology  
School of Medicine, Universidad de Sevilla, Av. Sanchez Pizjuan s/n,  
41009 Seville, Spain

### Deadline for manuscript submissions

31 May 2026



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/196593](https://mdpi.com/si/196593)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).